GR1008332B - Nanocarrier compositions - Google Patents

Nanocarrier compositions

Info

Publication number
GR1008332B
GR1008332B GR20140100218A GR20140100218A GR1008332B GR 1008332 B GR1008332 B GR 1008332B GR 20140100218 A GR20140100218 A GR 20140100218A GR 20140100218 A GR20140100218 A GR 20140100218A GR 1008332 B GR1008332 B GR 1008332B
Authority
GR
Greece
Prior art keywords
compositions
tigapotide
lipidic
nanocarrier compositions
dendrimeric
Prior art date
Application number
GR20140100218A
Other languages
Greek (el)
Inventor
Κωνσταντινος Νικολαου Δεμετζος
Αναστασια-Γεωργια Ιωαννη Πιππα
Αστεριος Ιωαννη Πισπας
Γρηγοριος Βυρωνος Σιβολαπενκο
Original Assignee
ΕΝΟΡΑΣΙΣ ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΚΑΙ ΙΑΤΡΙΚΩΝ ΥΛΙΚΩΝ ΚΑΙ ΜΗΧΑΝΗΜΑΤΩΝ με δ.τ. "ΕΝΟΡΑΣΙΣ Α.Ε.",
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ΕΝΟΡΑΣΙΣ ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΚΑΙ ΙΑΤΡΙΚΩΝ ΥΛΙΚΩΝ ΚΑΙ ΜΗΧΑΝΗΜΑΤΩΝ με δ.τ. "ΕΝΟΡΑΣΙΣ Α.Ε.", filed Critical ΕΝΟΡΑΣΙΣ ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΚΑΙ ΙΑΤΡΙΚΩΝ ΥΛΙΚΩΝ ΚΑΙ ΜΗΧΑΝΗΜΑΤΩΝ με δ.τ. "ΕΝΟΡΑΣΙΣ Α.Ε.",
Priority to GR20140100218A priority Critical patent/GR1008332B/en
Publication of GR1008332B publication Critical patent/GR1008332B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to novel compositions of tigapotide composed of polymeric, lipidic, dendrimeric and combined lipidic dendrimeric structures and their use in the treatment of disease. These nanocarrier compositions maximize the advantages of the drug delivery process of the novel colloid nanocarriers and consequently the biological properties (i. e. antitumoral) of tigapotide. Dynamic (DLS), static (SLS) and electrophoretic (ELS) light scattering were used to examine the size, the size distribution, the z-potential as well as the fractal dimension of the carriers in aqueous and biological media. The incorporation effectiveness of nanocarrier compositions was also studied.
GR20140100218A 2013-06-20 2013-06-20 Nanocarrier compositions GR1008332B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GR20140100218A GR1008332B (en) 2013-06-20 2013-06-20 Nanocarrier compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20140100218A GR1008332B (en) 2013-06-20 2013-06-20 Nanocarrier compositions

Publications (1)

Publication Number Publication Date
GR1008332B true GR1008332B (en) 2014-10-21

Family

ID=50792469

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20140100218A GR1008332B (en) 2013-06-20 2013-06-20 Nanocarrier compositions

Country Status (1)

Country Link
GR (1) GR1008332B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170220A1 (en) * 2000-10-16 2003-09-11 Procyon Biopharma Inc. Pharmaceutical preparations and methods for inhibiting tumors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170220A1 (en) * 2000-10-16 2003-09-11 Procyon Biopharma Inc. Pharmaceutical preparations and methods for inhibiting tumors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROBERT E. HAWKINS ET AL: "Safety and Tolerability of PCK3145, a Synthetic Peptide Derived from Prostate Secretory Protein 94 (PSP94) in Metastatic Hormone-Refractory Prostate Cancer", CLINICAL PROSTATE CANCER, vol. 4, no. 2, September 2005 (2005-09-01), pages 91 - 99, XP055102417 *

Similar Documents

Publication Publication Date Title
CL2019003433A1 (en) Ophthalmic pharmaceutical composition comprising mucopenetrating nanoparticles, the core of which comprises a pharmaceutical active agent selected from a receptor tyrosine kinase (rtk) inhibitor, or an angiogenesis inhibitor, and is coated with a surface modifying polymer; and use to treat an eye disorder (divisional application cl 2956-2014).
MX2019005287A (en) Cationic lipids for nucleic acid delivery and preparation thereof.
MX2021007794A (en) Compositions and methods for ophthalmic and/or other applications.
BR112018073671A2 (en) nanoparticle delivery compositions and methods of use
MX2014010808A (en) Targeting aminoacid lipids.
MY166014A (en) Combination therapy methods for treating proliferative diseases
MX2015008503A (en) Targeted conjugates encapsulated in particles and formulations thereof.
EA201391119A1 (en) DELIVERY SYSTEMS OF NANOPARTICLES, THEIR RECEIVING AND APPLICATION
PH12015501486B1 (en) Nanoparticle compositions of albumin and paclitaxel
MX2019013701A (en) Methods of enhancing drug delivery and effectiveness of therapeutic agents.
MX2012014079A (en) Biodegradable lipids for the delivery of active agents.
EA201491299A1 (en) CARBAMATIC CONNECTIONS, THEIR PRODUCTION AND APPLICATION
WO2016145008A3 (en) Mirna for treatment of breast cancer
MX2019002669A (en) Methods of treating behavioral symptoms of neurological and mental disorders.
MX2014012381A (en) Combination therapy for treating cancer.
EA201590654A1 (en) COMBINATION OF RASAGILIN AND PRIDOPIDINE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS, IN PARTICULAR OF HANTINGTON'S DISEASE
EA201591925A1 (en) THERAPEUTIC COMPOSITIONS AND THEIR APPLICATION
EA201391379A1 (en) PHARMACEUTICAL COMPOSITION FOR TREATING DISEASES IN THE ORAL CAVITY CONTAINING REBAMIPID
EP4124346A3 (en) Compositions and methods for treating diseases
EA201892797A1 (en) NANOPARTICLES FOR DELIVERY OF MEDICINES AND METHODS OF TREATMENT OF DRUG AND RESISTANT CANCER
WO2015153805A3 (en) Targeted polymerized nanoparticles for cancer treatment
MX2015015434A (en) Targeting corroles for tumor toxicity and mri.
GB2551453A (en) Nanocarrier delivery system for hydrophobic substances
CL2012003209A1 (en) Synthesis method of poly (lactic-glycolic acid) nanoparticles (plga) with pentoxifylline; pharmaceutical composition comprising nanoparticles of pest with pentoxifylline; and use of the nanoparticles loaded with pentoxifylline in the treatment of relief and prevention of chronic pain.
AR075686A1 (en) POLICOSANOL NANOPARTICLES

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20141121